Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Palbociclib
Related studies linked through entity extraction aliases.
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Study of Palbociclib in MLL-rearranged Acute Leukemias
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
- Status
- COMPLETED
- Phase
- PHASE3
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Study Of Palbociclib (PD-0332991) In Renal Impairment
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE3
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)
- Status
- COMPLETED
- Phase
- PHASE1
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2